Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing

Protara Therapeutics, Inc.

2022-Q3 EPS reported -$2.40

Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.
Cash and investments $107.1M as of Sep 30, 2022; expected to fund operations into 2H2024.
R&D expense $3.5M, down from $4.1M; G&A $4.5M, down from $6.7M year-over-year.
Phase 1a dose escalation of TARA-002 in NMIBC ongoing; Phase 2 in LMs expected to start in 2023 after FDA feedback.
IV Choline Chloride IFALD study ongoing; results to inform next steps.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protara Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $7.7 million, or $0.68 per share, EPS $0.68 per share.

Period: the third quarter ended September 30, 2022
Net income: net loss of $7.7 million, or $0.68 per share
EPS: $0.68 per share
Result: reported results

Exact text from the filing

Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-068819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.